

COMBINING DIAGNOSTICS AND  
THERAPEUTICS  
**PIONEERING  
PRECISION MEDICINE**

**Abeta active immunotherapy agreement with Takeda**

NASDAQ: ACIU | Investor Presentation - May 2024



# Disclaimer

*This presentation contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.*

*SupraAntigen<sup>®</sup> is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer<sup>®</sup> is a registered trademark of AC Immune SA in CH, CN, GB, JP, KR, NO and RU.*



COMBINING DIAGNOSTICS AND  
THERAPEUTICS  
**PIONEERING  
PRECISION MEDICINE**

**Abeta active immunotherapy agreement with Takeda**

NASDAQ: ACIU | Investor Presentation - May 2024






# Unique Abeta targeted active immunotherapy – ACI-24.060

Best-in-class SupraAntigen<sup>®</sup>-based active immunotherapy in Phase 2

- Generates antibody responses against toxic forms of Abeta (oligomeric and pyroGlu-Abeta)
- FDA Fast Track supports disruptive potential in Alzheimer’s disease treatment and prevention



**Abeta-specific**  
antibody response

---

Helper T-cells  
safely engaged  
**(Abeta-unrelated)**

## Unprecedented Performance

Immunogenicity	✓
Target & conformation specificity	✓
Avidity increase over time	✓
Sustainable response	✓
Boostable response	✓

**H1**

Initial Phase 2 ABATE **6-month AD data** on Abeta plaque reduction measured via PET imaging

**H2**

Phase 2 ABATE **12-month AD data<sup>1</sup>** on Abeta plaque reduction measured via PET imaging

(1) 12-month data will also include safety and immunogenicity results

# Landmark deal for ACI-24.060 in Alzheimer's disease

Supports promise of active immunization for neurodegenerative diseases



- Today's deal with Takeda covers AC Immune's unique, class-leading Abeta targeted active immunotherapy ACI-24.060



- Deal terms:
  - \$100 million upfront payment received for exclusive option to license global rights
  - Option exercise fee in the low-to-mid nine-figure range linked to ABATE clinical data
  - Up to approximately \$2.1 billion in potential payments including option exercise fee and development, commercial and sales-based milestones
  - Royalties in the mid-to-high teens on global sales



- Combines AC Immune's leadership in developing products for NDDs<sup>1</sup> with Takeda's clinical development expertise and history of driving neuroscience innovation

(1) Neurodegenerative diseases

# ABATE: Biomarker-based Phase 1b/2 study of ACI-24.060 in AD<sup>1</sup> and DS<sup>2</sup>

## Placebo-controlled Phase 1b/2 Study Overview


### Adaptive Study Design

Both	<ul style="list-style-type: none"> <li>Interim analyses of safety/tolerability &amp; immunogenicity</li> <li>Biomarker analyses including Abeta PET<sup>3</sup> and others</li> </ul>
AD	<ul style="list-style-type: none"> <li>Up to 4 different doses and/or dose regimens</li> <li>Expansion of one cohort to assess effect on Abeta PET</li> </ul>
DS	<ul style="list-style-type: none"> <li>Initiation using selected dose identified in AD (based on safety/tolerability and immunogenicity)</li> </ul>

### Outcome measures

Both	<ul style="list-style-type: none"> <li>Safety/tolerability</li> <li>Pharmacodynamics: Serum anti-Abeta antibody titers</li> <li><b>Abeta-PET imaging</b></li> <li>Exploratory biomarkers and clinical endpoints</li> </ul>
------	--







## Trial Schematic



(1) Alzheimer's disease; (2) Down syndrome-related AD; (3) Positron emission tomography; (4) AD participants must be between 50 – 85 years of age and have prodromal AD with Clinical Dementia Rating Global Score of 0.5 and Abeta pathology confirmed by PET scan; (5) Cohort comprised of non-demented people living with DS (age 35 – 50 years) and Abeta pathology confirmed by PET scan

# AC Immune technology platforms driving validating pharma deals




Strategy: optimize value to risk ratio and retain significant upside

<b>Platform</b>	 <b>SupraAntigen®</b>		 <b>Morphomer®</b>	
<b>Program</b>	ACI-24.060	ACI-35.030	Mor Tau	Tau PET
<b>Partner</b>				

■ An integrated approach to Central Nervous System (CNS)-specific therapies

# AC Immune strong track record in deals<sup>1</sup> with leading pharma co.s

Strategy: optimize value to risk ratio and retain significant upside

Program	Phase	Total value <sup>2</sup>	Upfront <sup>2</sup>	Milestones received <sup>2</sup>	Royalties	Partner
<b>ACI-24.060</b> (anti-Abeta active immunotherapy)	Phase 1b/2	>USD 2,100	USD 100		Mid-to-high teens	
<b>ACI-35.030</b> (anti-pTau active immunotherapy)	Phase 2b	CHF 500	CHF 26	CHF 20	Low-double digits to mid-teens	
<b>Tau Morphomer<sup>®</sup> drugs</b>	Phase 1 <sup>6</sup>	CHF 1,860	CHF 80 +USD 50 <sup>7</sup>	CHF 40	Low-double digits to mid-teens	
<b>PI-2620</b> (Tau PET <sup>4</sup> tracer)	Phase 3 <sup>5</sup>	EUR 160	EUR 0.5	EUR 7	Mid-single digits to low-teens	
<b>Crenezumab</b> (anti-Abeta antibody)	Phase 2	USD 65 <sup>3</sup>	USD 25	USD 40		*
<b>Semorinemab</b> (anti-Tau antibody)	Phase 2	CHF 59 <sup>3</sup>	CHF 17	CHF 42		*
<b>Total (millions)<sup>8</sup></b>		<b>CHF ~4,750</b>	<b>CHF 255.2 <sup>9</sup></b>	<b>CHF 147.4</b>		

■ Outstanding potential milestone payments exceed ~CHF 4.3 billion



(1) Disclosure limited due to confidentiality agreements with collaboration partners; (2) In millions; (3) Total payments received from partner until termination of agreement; (4) Positron emission tomography; (5) In Alzheimer's disease; (6) Phase 1 completed; (7) Equity investment; (8) Converted to CHF on date of receipt; (9) Excludes convertible note agreement of USD 50 million ; \* previously licensed to Genentech (a member of the Roche Group)



# AC Immune technology platforms driving validating pharma deals

Strategy: optimize value to risk ratio and retain significant upside

## Platform



## Unpartnered Programs

- a-syn active immunotherapy
- Anti-TDP-43 mAb<sup>1</sup>
- Anti-NLRP3-ASC mAb

- Mor-a-syn
- Mor-TDP-43 PET
- Mor-NLRP3-ASC

- Considerable additional potential value in our unpartnered clinical and preclinical programs

(1) Monoclonal antibody

# Conclusions

## AC Immune's leadership in precision medicine



Significant shareholder value is created through **class-leading active immunotherapies** in neurodegeneration



- Today's Takeda deal reinforces AC Immune's **track record** in deal execution
- >USD 4.5 billion in potential milestones from partnerships



- Clinically validated **technology platforms** continuously deliver **high-valued assets**
- Multiple **unpartnered assets against key targets** for development in-house and with potential partners



**Cash reserves** of CHF 104.8 million as of March 31, 2024, and **upfront payment** provides 3-year cash runway<sup>1</sup>

(1) assumes second ACI-35-related milestone payment of CHF25 million received in 2025 and no other milestones

# AC Immune: Pioneering science and precision medicine

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention